Real-time Quotes | Nasdaq Last Sale

Opening 10:00 12/02 EST
Corp Actions
Citigroup Downgrades Ovid Therapeutics to Neutral, Lowers Price Target to $4
Citigroup analyst Yigal Nochomovitz downgrades Ovid Therapeutics (NASDAQ:OVID) from Buy to Neutral and lowers the price target from $10 to $4.
Benzinga · 1h ago
The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Gets Temporary UK Authorization, Ovid's Trial Disappointment, Vanda Snags FDA Nod
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 1)
Benzinga · 2h ago
TG, OVID, FCEL and MESO among after-hours movers
Gainers: [[TG]] +29.6%. [[MESO]] +11.8%. [[FUBO]] +10.5%. [[VAPO]] +9.2%. [[SLQT]] +6.5%.Losers: [[OVID]] -48.7%. [[FCEL]] -16.8%. [[IRTC]] -16.1%. [[SOL]] -13.2%. [[RETA]] -9.1%.
Seekingalpha · 15h ago
Ovid Therapeutics misses goal in Angelman syndrome treatment
Ovid Therapeutics (OVID) -44.8% post-market after saying its Phase 3 Neptune clinical trial of OV101 (gaboxadol) for the treatment of Angelman syndrome failed to meet its primary endpoint.The late-stage study
Seekingalpha · 16h ago
Ovid Therapeutics Announces Phase 3 NEPTUNE Clinical Trial of OV101 for the Treatment of Angelman Syndrome Did Not Meet Primary Endpoint
* OV101 program in Angelman syndrome to pause pending full analysis of NEPTUNE trial and discussions with FDA * Pivotal studies of OV935 (soticlestat) in Dravet syndrome and Lennox-Gastaut syndrome expected to begin in the First Half of 2021NEW YORK, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced topline results from the Company’s Phase 3 NEPTUNE clinical trial of OV101 (gaboxadol) for the treatment of Angelman syndrome.NEPTUNE is a randomized, double-blind, placebo-controlled, Phase 3 study that enrolled and treated 97 patients diagnosed with Angelman syndrome, 4-12 years of age, and 7 patients diagnosed with Angelman syndrome ages 2-3 years for safety and pharmacokinetic evaluation only. The study was designed to assess the effects of treatment with OV101 (oral, once-daily dosing) versus placebo over 12 weeks. The sole primary endpoint was change in overall score on the Clinical Global Impression-Improvement-Angelman syndrome (CGI-I-AS) scale. Secondary endpoints included sleep, communication, motor function, socialization, daily living skills and behavior domains.The primary endpoint of the NEPTUNE study was not achieved. Patients given OV101 showed a 0.7 point improvement in CGI-I-AS over baseline while placebo also showed a 0.8 point improvement in CGI-I-AS (p=NS). Secondary endpoints continue to be evaluated, although initial results show no difference between OV101 and placebo.OV101 was well-tolerated, with no significant safety issues observed. Ovid plans to complete a full analysis of the results of the NEPTUNE study and discuss these results with the U.S. Food and Drug Administration (FDA) to determine next steps, if any, for the program. The Company will continue to offer study drug to patients enrolled in the open-label extension trial (ELARA) pending further analysis of the NEPTUNE study. The Company expects to report data from the ELARA study in the first quarter of 2021.“We are deeply disappointed with the outcome of the NEPTUNE trial which did not achieve its primary endpoint,” said Jeremy Levin, DPhil, MB, BChir, Chairman and Chief Executive Officer of Ovid Therapeutics. “Other than the ongoing ELARA study, we plan to pause our OV101 program in Angelman syndrome pending a full understanding of this outcome and discussions with regulators and investigators.”Dr. Levin added: “For now, the focus of our future development efforts will concentrate on the development of our other late-stage asset, OV935, in two rare epilepsies: Dravet and Lennox-Gastaut syndromes. With our partner Takeda, we plan to initiate pivotal trials in these conditions in the first half of 2021.”“NEPTUNE is our first study focused on the pediatric and adolescent population in Angelman syndrome, and we will fully assess all the data from this trial to understand this outcome and determine next steps, if any, for OV101 in this and other conditions, including Fragile X syndrome,” said Amit Rakhit M.D., President and Chief Medical Officer. “We are sincerely grateful for the commitment and dedication of patients, families, investigators and employees to this program, and in particular, to those who participated in the NEPTUNE trial.”About OV101 (gaboxadol) OV101 (gaboxadol) is a delta (δ)-selective GABAA receptor agonist. These receptors are thought to have a central role in tonic inhibition, a key physiological process of the brain believed to be a core pathophysiology underlying certain neurodevelopmental disorders.About Angelman Syndrome Angelman syndrome is a rare genetic condition that is characterized by a variety of signs and symptoms. Characteristic features of this condition include delayed development, intellectual disability, severe speech impairment, problems with movement and balance, seizures, sleep disorders and anxiety.About Ovid Therapeutics Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines in development. The Company is developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of rare developmental and epileptic encephalopathies (DEEs). OVID is evaluating OV101 (gaboxadol) for the treatment of Angelman syndrome and Fragile X syndrome. For more information on Ovid, please visit Statements This press release includes certain disclosures that contain “forward-looking statements,” including, among other things, statements regarding uncertainties regarding the impact of the NEPTUNE trial results on the clinical development of OV101 in Angelman syndrome, likelihood that data will support future development, the association of data with treatment outcomes, the design, progress, timing, scope and results of the Company’s clinical trials, the anticipated timing of disclosure of results of clinical trials and the likelihood of obtaining regulatory approval of Ovid’s product candidates. You can identify forward-looking statements because they contain words such as “will,” “appears,” “believes” and “expects.” Forward-looking statements are based on Ovid’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include uncertainties in the development and regulatory approval processes, and the fact that initial data from clinical trials may not be indicative, and are not guarantees, of the final results of the clinical trials and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and/or more patient data become available. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth in Ovid’s filings with the Securities and Exchange Commission under the caption “Risk Factors.” Such risks may be amplified by the COVID-19 pandemic and its potential impact on Ovid’s business and the global economy. Ovid assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.ContactsInvestors and Media: Ovid Therapeutics Inc. Investor Relations & Public Relations irpr@ovidrx.comORInvestors: Argot Partners Maeve Conneighton/Dawn Schottlandt 212-600-1902 ovid@argotpartners.comMedia: Dan Budwick 1AB
GlobeNewswire · 17h ago
The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions
Biotech stocks had a rather uneventful week, as the sector was seen mostly flatlining amid light trading volume ahead of the Thanksgiving holiday.
Benzinga · 3d ago
Are Options Traders Betting on a Big Move in Ovid Therapeutics (OVID) Stock?
Zacks · 11/25 13:51
Ovid Therapeutics Reports Will Present 2 Presentations At American Epilepsy Society Virtual Congress Dec. 4-8
Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that abstracts from the
Benzinga · 11/23 21:02
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OVID. Analyze the recent business situations of Ovid through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts


Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OVID stock price target is 14.40 with a high estimate of 21.00 and a low estimate of 10.00.
Institutional Holdings
Institutions: 125
Institutional Holdings: 27.58M
% Owned: 43.47%
Shares Outstanding: 63.44M
Sold Out
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Biotechnology & Medical Research
Pharmaceuticals & Medical Research
Key Executives
Chairman/Chief Executive Officer/Director
Jeremy Levin
Amit Rakhit
Executive Vice President - Finance/Controller/Treasurer
Timothy Daly
Senior Vice President
Dirk Haasner
Chief Compliance Officer/General Counsel/Secretary
Thomas Perone
Jason Tardio
Lead Director/Independent Director
Bart Friedman
Independent Director
Karen Bernstein
Independent Director
Barbara Duncan
Independent Director
Douglas Williams
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About OVID
Ovid Therapeutics Inc. (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist. Ovid is developing OV101 for use in both Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and relieve several of the symptoms of these disorders. Ovid has initiated the Phase II STARS trial of OV101 in adults with Angelman syndrome and a Phase I trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.
Hot Stocks

Webull offers kinds of Ovid Therapeutics Inc stock information, including NASDAQ:OVID real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OVID stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OVID stock methods without spending real money on the virtual paper trading platform.